Introduction
Chronic lymphocytic leukemia (CLL) is an incurable malignancy of mature B lymphocytes, which progressively accumulate in the peripheral blood (PB), bone marrow (BM) and lymph nodes (LNs). The interaction of CLL cells with accessory cells, the extracellular matrix and soluble factors within the lymphoid microenvironment is essential for CLL cell proliferation and survival (1) . CLL cells within lymphoid compartments display an activated CD69+ phenotype (2) , and their proliferation occurs adjacent to CD40 ligand (CD40L) expressing CD4+ T cells and stromal cells within so-called proliferation centers (3, 4) . This and further evidence (5, 6) , led to the widely accepted concept, that CD4+ T lymphocytes play an essential role in CLL cell activation, proliferation and survival. CD40L, a TNF-alpha superfamily member expressed on activated T cells, has been described as key mediator of T cell-driven CLL responses, acting in concert with T cell derived cytokines (7) (8) (9) (10) .
Healthy T cell-dependent immune responses require the dynamically regulated positioning of B cells to specialized lymphoid subcompartments, which facilitate B cell activation, proliferation and differentiation (11) . Activating stimuli alter the responsiveness of chemokine and adhesion receptors and thereby determine B cell migration and retention. LN chemokines co-immobilized to extracellular matrix molecules serve as the respective directional cues (12, 13) .
In CLL, little is known about the stop and go signals involved in malignant B cell positioning within the infiltrated LNs, displaying a completely disrupted architecture. CD44 interactions with the extracellular matrix glucosaminoglycan hyaluronan (HA) participate in lymphocyte activation, migration and tissue retention. The CD44 family (panCD44) comprises diverse isoforms, resulting from alternative splicing of 9 variant exons and extensive posttranslational glycosylations and glucosaminoglycan additions. Concomitantly, the HA binding ability of the CD44 molecule is strictly controlled in a cell-type specific manner by CD44 clustering, CD44 variant isoform (CD44v) (14) or glycoform expression (15, 16) . In particular, Author Manuscript Published OnlineFirst on November 1, 2012; DOI: 10.1158/0008-5472. CAN-12-2749 leukocytes mainly express the standard CD44 isoform (CD44s), which lacks all variant exons, and require stimulation to recognize HA.
Correlative studies have suggested CD44 as a negative prognostic marker in CLL (17) (18) (19) but the underlying molecular mechanisms are not fully understood. Here, we aimed to examine the role of CD44-HA interactions for CLL cell positioning within LN compartments. We observed an activation-induced, CD44-mediated adhesion to HA, which was accompanied by increased expression of CD44v6 displaying N-linked glycosylations. We propose that the CD40L-dependent CLL cell activation within LNs may provide a stop signal to motile CLL cells by inducing high avidity CD44-HA interactions, thus contributing to their retention required for survival and proliferation.
Methods
Patient samples. Following informed consent, blood samples were obtained from CLL patients, which were chemonaive or had not received chemotherapy during the last 6 months, at the Third Medical Department Salzburg. Peripheral blood mononuclear cells (PBMCs) were obtained by density gradient centrifugation, viably frozen and stored in liquid nitrogen.
Thawed PBMCs were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) and antibiotics. For functional assays CLL cells were enriched untouched using the EasySep Kit (Stem Cell Technologies). For RNA and protein isolation CLL cells were positively isolated via CD19 microbeads (MACS, Miltenyi). Primary mesenchymal stromal cell cultures were established from BM aspirates from healthy donors as described (20 panCD44 or CD44 variant exon specific primers as previously described (22) and visualized by 1% agarose ethidium bromide gels.
Immunoblotting.
Immunoblotting under denaturing and reducing conditions was performed as described (23) using mAbs specific for panCD44 (clone SFF-304), CD44v3 or CD44v6.
For deglycosylation whole cell lysates were digested by PNGase F according to the manufacturer's directions.
Statistical analysis. Statistical analysis was performed using GraphPad Prism 5.0. All data were tested for normal distribution by the Kolmogorov-Smirnov test. Normally distributed data were analyzed by paired t test, non-normally distributed by Wilcoxon matched pairs test.
Differences were considered statistically significant when p<0.05.
Results

HA and CCL21 are co-localized within the reticular network of CLL LNs and collectively trigger the robust motility of CLL cells
To identify which LN areas could facilitate CLL cell interactions with HA, we evaluated the HA distribution pattern in LN sections of CLL patients. We found that HA was highly abundant throughout the infiltrated LNs, including sites of low proliferation ( Figure Figure 1E ). CD44 blockage with the mAb clone IM7 did not affect the cell motility ( Figure 1F ), while blockage using a different clone (515) even enhanced the motile response (data not shown), suggesting that HA-mediated motility in CLL was triggered by a CD44 independent pathway(s). This is in line with previous observations describing HA/IL-8-induced motility of CLL cells being mediated by the receptor for hyaluronan-mediated motility (RHAMM) (24) .
To verify that CLL cells simultaneously encounter HA and CCL21 in vivo, we next assessed their relative distribution by fluorescence co-stainings. CCL21 was distributed throughout the infiltrated LNs, and co-localized with HA at the reticular network, previously suggested to serve as guiding structure for leukocyte migration ( Figure 1G ) (25) . Figure 3C ), which was not affected by the presence of CCL21 (data not shown). Furthermore, the ability of CD40L to stimulate CD44 adhesiveness to HA appeared specialized, because CLL adhesion to other ECM ligands like fibronectin, collagen type I, and laminin remained negligible (data not shown).
CD40L-induced CD44-HA bonds "lock" CLL cells to HA and overrule CCL21-mediated promigratory signals
To confirm that the high avidity CD44-HA interactions by themselves are responsible for the reduced motility of CD40L activated CLL cells on HA/CCL21, we blocked these interactions by preincubation with saturating amounts of soluble HA (sHA). Indeed, this restored the motile phenotype of CD40L-stimulated CLL cells on the HA/CCL21 substrate ( Figure 4A ). confirming its blocking effect on CD44-HA bonds (Figure 4B, left) . Instead, cell rolling under shear force was increased ( Figure 4B, right) , pointing to HA-dependent interactions of a lower strength. These results show that CD40L-activation per se did not alter the migratory potential of CLL cells on HA/CCL21 but induced strong CD44-mediated adhesions to HA, which locked CLL cells to the substrate and thereby overruled the CCL21-mediated promigratory signal.
CD40L-stimulation elevates panCD44 levels and induces the expression of the variant isoforms CD44v3 and CD44v6
The differential capacity of CD44 on unstimulated and CD40L-activated CLL cells to bind HA led us to investigate potential alterations in their panCD44 levels or structural changes within the expressed CD44 repertoire. We found a transcriptional upregulation of panCD44 upon CD40L-activation ( Figure 5A ), which translated into a significantly increased surface expression ( Figure 5B ). However, all CLL patients, irrespective of their clinical risk profile, uniformly displayed high panCD44 levels on PB CLL cells, which poorly bound HA (Supplementary Figure S4) . Therefore, the induction of HA binding only by increased panCD44 surface levels is improbable and we investigated CD44v expression of CLL cells. 
CD40L-activation potentiates the adhesion of CLL cells to primary stromal cells in a CD44-dependent manner
Stromal contact within the LN microenvironment is thought to support CLL outgrowth and survival. Therefore, we determined the importance of CD44-mediated adhesions to HAbearing primary mesenchymal stromal cells. We found that CD40L-stimulation highly increased CLL cell adhesion compared to unstimulated control cells (Figure 7) , which was largely CD44-mediated as shown by blocking experiments. An isotype matched control mAb had no effect (data not shown). The adhesion was also HA dependent, as HAase treatment of stromal cells decreased CLL cell adhesion (Figure 7) . Tumor-driving CD44-HA interactions have been described in a variety of cancers (27) . In CLL, elevated CD44 serum levels and high panCD44 as well as CD44v surface levels have been suggested as prognostic markers. While apparent consensus exists on the association of high CD44 serum levels with poor clinical outcome (17, 18, 28) , the prognostic relevance of panCD44 and CD44v surface levels on circulating CLL cells remains arguable. Our data do not support a prognostic value of high CD44 levels on PB CLL cells. Instead, we suggest 
to assume that CD44 is shed from the CLL cell surface by e.g. matrix metalloproteinases (29) after proliferation to disrupt their anchorage on the HA substrate and to restore their interstitial motility. This shedding might account for the increased CD44 serum levels observed in CLL cases with high proliferative activity. Where indicated CLL cells were pretreated with a blocking anti-CD44 mAb or isotype control (IgG 1 ) (n=6, right). *p<0.05; **p<0.01;***p<0.001. 
